Health
Immunotherapy extends survival in patients with advanced bladder cancer – News-Medical.Net
An immunotherapy drug called ‘avelumab’ has been shown to significantly improve survival in patients with the most common type of bladder cancer, according to results from a phase III clinical trial led by Queen Mary University of London and Barts Cancer Cent…
Reviewed by Emily Henderson, B.Sc.Sep 18 2020
An immunotherapy drug called ‘avelumab’ has been shown to significantly improve survival in patients with the most common type of bladder cancer, according to results from a phase III clinical trial led by Queen Mary University of London and Barts Cancer Centre, UK.
This is the first time an immune therapy has resulted in a survival advantage in this setting in bladder cancer, and will potentially benefit thousands of patients each year.
The resul…
-
Noosa News16 hours agoFull house as Minister shares vision for Sunshine Coast transport
-
General15 hours agoWill AI solve our productivity problem or increase unemployment?
-
Business13 hours agoWhy I’d buy these top ASX 200 shares next
-
Business11 hours ago10 reasons to buy and hold this tech stock forever